Skip to main content

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · IEX Real-Time Price · USD
12.50
-0.23 (-1.81%)
After-hours:Oct 22, 2021 7:59 PM EDT
12.73
-0.02 (-0.16%)
At close: Oct 22, 4:00 PM
Market Cap1.02B
Revenue (ttm)175.01M
Net Income (ttm)35.29M
Shares Out82.74M
EPS (ttm)0.58
PE Ratio22.14
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,324,602
Open12.16
Previous Close12.75
Day's Range11.73 - 12.77
52-Week Range10.76 - 94.17
Betan/a
AnalystsStrong Buy
Price Target16.67 (+31.0%)
Est. Earnings DateNov 11, 2021

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed ...

IndustryPharmaceuticals
IPO DateOct 30, 2020
Employees49
Stock ExchangeNASDAQ
Ticker SymbolAVIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AVIR stock is "Strong Buy." The 12-month stock price forecast is 16.67, which is an increase of 30.95% from the latest price.

Price Target
$16.67
(30.95% upside)
Analyst Consensus: Strong Buy

News

Why Atea Pharmaceuticals Stock Got Crushed This Week

A mid-stage trial miss caused investors to hit the exits this week.

4 hours ago - The Motley Fool

Atea (AVIR) Plunges on Oral COVID Candidate Study Failure

Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.

2 days ago - Zacks Investment Research

Why Atea Pharmaceuticals Is Imploding Today

The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.

3 days ago - The Motley Fool

AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Pharmaceuticals Plunging Today

Atea Pharmaceuticals (AVIR) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. The post AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Phar...

3 days ago - InvestorPlace

Atea Pharma's Covid antiviral misses mark in mid-stage trial

CNBC's Meg Tirrell joins 'Squawk Box' to report on Atea Pharmaceuticals' Roche-partnered Covid-19 antiviral, which missed its primary goal in a phase 2 trial.

3 days ago - CNBC Television

Atea Pharma's COVID-19 treatment fails to meet study goal; shares plunge

(Reuters) -A mid-stage trial testing Atea Pharmaceuticals' COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in non-hospitalized patients with mild or moderate d...

3 days ago - Reuters

Why Are Atea Pharmaceuticals Shares Plunging Today?

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related:   Atea Unveils Trial Am...

3 days ago - Benzinga

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatie...

Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms

3 days ago - GlobeNewsWire

3 Stocks to Consider if the October Stock Market Sell-Off Worsens

These stocks could be attractive at discounted prices.

Other symbols:IONSMRK
5 days ago - The Motley Fool

3 COVID Stocks That Can Turn $1,000 Into $10,000

Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.

Other symbols:DOCSTXG
1 week ago - The Motley Fool

Which COVID-19 Pill Stock Is the Best Buy?

Merck, Pfizer, and Atea are set to do battle next year in the COVID-19 pill market.

Other symbols:MRKPFE
2 weeks ago - The Motley Fool

2 Best Biotech Stocks to Buy In October

Atea Pharmaceuticals and Ocugen may be gearing up for a stellar October.

Other symbols:OCGN
2 weeks ago - The Motley Fool

3 Stocks That Might Soar With Pills for COVID

Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector.

Other symbols:MRKPFE
2 weeks ago - The Motley Fool

Why Atea Pharmaceutical Stock Is Ripping Higher Today

This biotech's experimental COVID-19 medication could be a big winner.

Other symbols:MRK
3 weeks ago - The Motley Fool

Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executi...

3 weeks ago - GlobeNewsWire

Why Atea Pharmaceuticals Is Up 17% Today

Orally administered treatments of COVID-19 infections are coming into focus as vaccine stocks lose their luster.

1 month ago - The Motley Fool

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:HSTONRBONVIVPRVBSYN
1 month ago - InvestorPlace

Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executi...

1 month ago - GlobeNewsWire

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against...

BOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vit...

1 month ago - GlobeNewsWire

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught app...

Other symbols:JNJMRKMRNAPFESRNEVXRT
2 months ago - InvestorPlace

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and aud...

2 months ago - GlobeNewsWire

This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money

An effective oral antiviral therapy for the coronavirus may be around the corner.

Other symbols:GILDMRK
2 months ago - The Motley Fool

Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference

BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for...

3 months ago - GlobeNewsWire

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19.  Roche Holding AG (OTC: RHH...

3 months ago - Benzinga

Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY...

4 months ago - Benzinga